期刊文献+

成人噬血细胞性淋巴组织细胞增生症的临床特征及预后分析 被引量:2

Clinical features of 41 cases of adult hemophagocytic lymphohistiocytosis and prognosis analysis
下载PDF
导出
摘要 目的分析成人噬血细胞性淋巴组织细胞增生症(hemophagocytic lymphohistiocytosis,HLH)的临床特征,探讨影响其预后的危险因素。方法回顾性研究复旦大学附属华山医院2006—01~2012—05收治的41例HLH患者临床、实验室检查等资料,采用多因素分析法对预后相关危险因素进行研究。结果发热、关节肌肉症状、肝脾大是HLH最为常见的临床特征,皮疹、腹泻则相对少见;而实验室检查方面最具特征性的表现为全血细胞减少、高甘油三酯血症、低纤维蛋白原血症、铁蛋白显著升高,以及骨髓噬血细胞现象;多浆膜腔积液、伴发感染和低血小板计数是HLH预后不良的独立危险因素,其中血小板计数〈5×10^9/L是最强危险因素(OR:71.5,95%CI=2.48~2061)。结论成人HLH病情严重,预后凶险,病死率极高,多浆膜腔积液、伴发感染和低血小板计数(〈5×10^9/L)是影响其预后的主要因素。 Objective To evaluate the clinical features of hemophagocytic lymphohistiocytosis (HLH) in adult and to discuss the risk factors affecting the prognosis. Methods Forty - one patients with HLH who admitted to Huashan Hospital, Fudan University from January 2006 to May 2012 were reviewed retrospectively. Clinical features and laboratory information were collected. Multivariate analysis was conducted to analyze the risk factors. Results Fever, articular and muscular symptoms and hepatosplenomegaly were the most common clinical features of HLH. Rash and diarrhea were relatively rare. The most common laboratory findings were pancytopenia, hypertriglyceridemia, hypofibrinogenemia, significant elevation in serum ferritin levels and hemophagocytosis in bone marrow. Multiple serous cavity effusion, infection and lower platelet count were independent risk factors of poor prognosis. Platelet count less than 5 x 109/L was the most powerful risk factor(OR = 71.5, 95% CI = 2. 48 ~ 2061 ) Conclusion Adult HLH is a serious disease with an extremely poor outcome which leading to high mortality. Multiple serous cavity effusion, infection and lower platelet count less than 5 x 109/L are the main factors which affect the prognosis.
出处 《中国急救医学》 CAS CSCD 北大核心 2014年第3期212-215,共4页 Chinese Journal of Critical Care Medicine
关键词 噬血细胞性淋巴组织细胞增生症(HLH) 感染 血小板 预后 危险因素 Hemophagocytic lymphohistiocytosis(HLH) Infection Platelet Prognosis Risk factor
  • 相关文献

参考文献11

  • 1Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders[ J ]. Curr Opin Allergy Clin Immunol, 2006, 6 ( 6 ) : 410 -415.
  • 2Henter JI, Home A, Arico M, et al. HLH - 2004 : diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[ J]. Pediatr Blood Cancer, 2007, 48(2): 124-131.
  • 3李国辉,范玉贞,郝淼旺,黄斯勇,刘利,杨健,梁英民.噬血细胞综合征30例临床分析[J].临床血液学杂志,2011,24(3):276-278. 被引量:8
  • 4Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis [J]. Arch Dis Child, 1952, 27(136) : 519 -525.
  • 5季彦格,毛彦娜,刘炜,赵瑞,宋丽丽,高海丽,李慧霞,张红梅.儿童噬血细胞综合征预后危险因素分析[J].中华血液学杂志,2011,32(12):836-839. 被引量:6
  • 6Qiang Q, Zhengde X, Shuang Y, et al. Prevalence of coinfection in children with Epstein - Barr virus - associated hemophagocytic lymphohistiocytosis[J]. J Pediatr Hematol Oncol, 2012, 34(2) : e45 - 48.
  • 7Tseng YT, Sheng WH, Lin BH, et al. Causes, clinical symptoms, and outcomes of infectious diseases associated with hemophagocytie lymphohistiocytosis in Taiwan Residents adults [ J ]. J Mierobiol Immunol Infeet, 2011,44(3) : 191 -197.
  • 8Sung L, King SM, Careao M, et al. Adverse outcomes in primary hemophagoeytie lymphohistiocytosis[ J]. J Pediatr Hematol Oneol, 2002, 24 (7) : 550 - 554.
  • 9Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagoeytie lymphohistiocytosis [ J ]. Blood, 2011, 118 ( 15 ) : 4041 - 4052.
  • 10Balamuth NJ, Nichols KE, Paessler M, ct al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus - associated hemophagocytic lym- phohistioeytosis[ J]. J Pediatr Hematol Oneol, 2007, 29 ( 8 ) : 569 - 573.

二级参考文献18

  • 1HENTER J I, HOME A, AFICO M, et al. HLH-2004 : di- agnostic and therapeutic guidelines for hemophagocytic ly- mohohistiocytosis[J]. Pediatr Blood Cancer, 2007,48 : 124- 131.
  • 2JANKA G E. Familial and acquired hemophagocytic lym- phohistiocytosis[J]. Eur J Pediatr, 2007,166: 95- 109.
  • 3IMASHUKU S, HIBI S,OHARA T,et al. Effective control of Epstein-Barr virus related hemophagocytie lymphohistio- cytosis with imrnunochemotherapy [J]. Blood, 1999, 93: 1869-1874.
  • 4CHEN J S,LIN K H,LIN D T,et al. Longitudinal obser- vation and outcome of non-familial childhood haemophago- cytic syndrome receiving etoposide-containing regimens[J]. Br J Haematol,1998,103:756-762.
  • 5OST A, NILSSON-ARDNOR S, HENTER J I. Autopsy findings in 27 children with haemophagocytic lymphohistio- cytosis[J]. Histopathology, 1998,32 : 310- 316.
  • 6EMMENEGGER U,SCHAER D J,LARROCHE C,et al. Haemophagocytic syndromes in adults: current concepts and challenges ahead[J]. Swiss Med Wkly, 2005,135 : 299 -314.
  • 7Ohga S, Kudo K, lshii E, et al. Hematopoietic stem cell trans- plantation for familial hemophagoeytic lymphohistiocytosis and Epstein-Ban" virus-associated hemophagocytic lymphohistiocytosis in Japan. Pedtiatr Blood Cancer, 2010, 54:299-306.
  • 8Risdall R J, Mckenna RW, Nesbit ME, et al. Virus-associated he- mophagncytic syndrome: a benign histiocytic proliferationdistinct frommalignant histiocytosis. Cancer, 1979, 44:993-1002.
  • 9Henter JI, Home A, Arico M, el al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Ped- iatr Blood Cancer,2007,48 : 124-131.
  • 10Chuang HC, Lay JD, Hsieh WC, et al. Pathogenesis and mecha- nism of disease progression from hemophagocytic lymphohistiocyto- sis to Epstein-Barr virus-associated T-cell lymphoma:nuclear fac- tor-kappa B pathway as a potential therapcutic target. Cancer Sci, 2007, 98 : 1281-1287.

共引文献12

同被引文献27

  • 1陈捷,吴颖,田红.淋巴瘤相关性嗜血细胞综合征28例临床诊治分析[J].实用医学杂志,2007,23(17):2714-2716. 被引量:8
  • 2Janka GE, Lehmberg K .Hemophagocytic syndromes —an update[J]. Blood Rev, 2 014,28(4):135-142.
  • 3Henter JI, Horne AC, Arico M, ef al.HLH-2004: Diagnostic and therapeuticguidelines for hemophagocyticlymphohistiocytosisUl- Pediatr BloodCancer, 2007, 48(2):124-131.
  • 4Shipp MA. A predictive modelfor aggressive non-Hodgkin’slymphoma. The International Non-Hodgkin *s Lymphoma PrognosticFactors Project[J]. N Engl J Med, 1993,329(14):987-994.
  • 5Cheson BD, Pfistner B, Juweid ME,et a/. Revised response criteria formalignant lymphoma[J]. J Clin Oncol,2007, 25(5):579-586.
  • 6Lin N, Song Y, Zheng W, et a/.A prospective phase II study ofZ.-asparaginase-CHOP plus radiationin newly diagnosed extranodal NK/T-cell lymphoma, nasal typeL)]- JHematol Oncol, 201 3(6):44.
  • 7Yong W, Zheng W, Zhu J, et al./.-asparaginase in the treatment ofrefractory and relapsed extranodalNK/T-cell lymphoma, nasal type[J].Ann Hematol, 2009, 88(7):647-652.
  • 8Riviere S, Galicier L, Coppo P, et al.Reactive hemophagocytic syndromein adults: A multicenter retrospectiveanalysis of 162 patients[J]. Am J Med,2014,127(1 1):1 1 18-1 125.
  • 9Han AR, Lee HR, Park BB, eta/. Lymphoma-associated hemophagocytic syndrome:clinical features and treatmentoutcome[J]. Ann Hematol, 2007,86(7):493-498.
  • 10Han L, Li L, Wu J, et al. Clinicalfeatures and treatment ofnatural killer/T cel I lymphomaassociated with hemophagocyticsyndrome: comparison with otherT cell lymphoma associated withhemophagocytic syndromeLJ]. LeukLymphoma, 2014, 55(9):2048-2055.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部